The renoprotective potential of endothelin receptor antagonists

Thomas Knoll Department of Urology and Department of Medicine University Hospital Mannheim, University of Heidelberg, Germany Faculty of Clinical Medicine of the University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68135 Mannheim, Germany. [email protected]

Meike Schaub Department of Urology and Department of Medicine University Hospital Mannheim, University of Heidelberg, Germany Faculty of Clinical Medicine of the University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68135 Mannheim, Germany. [email protected]

Rainer Birck Department of Urology and Department of Medicine University Hospital Mannheim, University of Heidelberg, Germany Faculty of Clinical Medicine of the University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68135 Mannheim, Germany. [email protected]

Claude Braun Department of Urology and Department of Medicine University Hospital Mannheim, University of Heidelberg, Germany Faculty of Clinical Medicine of the University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68135 Mannheim, Germany. [email protected]

Klaus-Peter Juenemann Department of Urology and Department of Medicine University Hospital Mannheim, University of Heidelberg, Germany Faculty of Clinical Medicine of the University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68135 Mannheim, Germany. [email protected]

Peter Rohmeiss Department of Urology and Department of Medicine University Hospital Mannheim, University of Heidelberg, Germany Faculty of Clinical Medicine of the University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68135 Mannheim, Germany. [email protected]

Abstract

The endothelin system has been identified as having a substantial role in renal failure, both acute and chronic. Beside its well characterised haemodynamic effects, its mitogenic and pro-fibrotic properties have gained increased interest in the pathophysiology of chronic renal failure. This review outlines the role of endothelin in the pathogenesis of various renal diseases with a special focus on the potential of blocking this system with endothelin receptor antagonists. So far, most data were derived from animal models, but they provide strong evidence that endothelin receptor antagonists may represent a powerful therapeutic strategy in ameliorating the course of acute and chronic renal failure.

Keywords

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The renoprotective potential of endothelin receptor antagonists

Information for

Open access

Opportunities

Help and information

The renoprotective potential of endothelin receptor antagonists

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature